Abstract
The prevalence and clinical relevance of TP53 and PIK3CA mutations in pretreatment breast cancer have been previously reported. However, little is known regarding these mutations in residual tumor tissues after neoadjuvant chemotherapy. Here, we investigated the association between TP53 and PIK3CA mutations in residual disease and survival of breast cancers. TP53 and PIK3CA somatic mutations were examined in 353 post-neoadjuvant chemotherapy residual tumor tissues by Sanger sequencing. Survival curves of patients with TP53 and PIK3CA mutations were compared using the Kaplan-Meier method. Fifty-six (15.9%) of the 353 patients carried a TP53 somatic mutation and 79 patients (22.4%) carried a PIK3CA somatic mutation. A total of 18 patients carried co-mutation of TP53 and PIK3CA. Patients with somatic co-mutation were more likely to have high-grade tumors (35.3% vs. 10.6%, P = 0.010), estrogen receptor-negative tumors (55.6% vs. 26.7%, P = 0.009), progesterone receptor-negative tumors (61.1% vs. 30.5%, P = 0.008) and triple-negative tumors (35.3% vs. 13.3%, P = 0.025) compared with non-carriers. More importantly, co-mutation of TP53 and PIK3CA carriers had a significantly worse disease-free survival (DFS) and distant disease-free s...Continue Reading
References
Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·Keith N OgstonSteven D Heys
Dec 1, 2005·Breast Cancer Research and Treatment·Shao Ying LiBarry Iacopetta
Dec 3, 2005·Cancer Research·Steven J IsakoffJoan S Brugge
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Magali OlivierAnne-Lise Børresen-Dale
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gizeh Pérez-TenorioOlle Stål
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin KalinskyMary Ellen Moynahan
Aug 18, 2009·International Journal of Cancer. Journal International Du Cancer·Elena López-KnowlesRobert L Sutherland
Feb 18, 2011·Cancer Research·Jessica R AdamsSean E Egan
Feb 15, 2012·Breast Cancer Research : BCR·Magdalena CizkovaIvan Bièche
Jun 23, 2012·Nature·Philip J StephensMichael R Stratton
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Dec 21, 2013·Cancer Discovery·Justin M BalkoCarlos L Arteaga
Feb 18, 2014·Lancet·Patricia CortazarGunter von Minckwitz
May 8, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laxmi Silwal-PanditAnita Langerød
Jun 14, 2014·Cancer Research·Yi-Zhou JiangZhi-Ming Shao
May 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hua YuanYuntao Xie
Jun 23, 2015·Nature Medicine·Lucy R YatesPeter J Campbell
Aug 5, 2015·International Journal of Cancer. Journal International Du Cancer·Yuxia WangYuntao Xie
Aug 13, 2015·Nature·Alexandra Van KeymeulenCédric Blanpain
Feb 10, 2016·Nature Reviews. Clinical Oncology·Frederique Penault-Llorca, Nina Radosevic-Robin
Jul 13, 2016·Molecular Oncology·Bhushan Thakur, Pritha Ray
Feb 13, 2017·Breast Cancer Research and Treatment·Sarah CroessmannBen Ho Park
Oct 7, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Laura SpringAditya Bardia
Apr 24, 2018·Cell·Charissa KimNicholas E Navin
Citations
Sep 24, 2020·Journal of Cellular and Molecular Medicine·Zijian LiuLiling Zhang
Jul 5, 2019·Journal of Cancer Research and Clinical Oncology·C ElfgenZ Varga
Jan 8, 2020·Cancers·Ali AlqahtaniHafez Halawani
May 19, 2020·Cell Proliferation·Jiajian WangHongli Du
Dec 11, 2020·Leukemia·Montserrat EstruchKim Theilgaard-Mönch
Mar 4, 2021·Medicine·Shuang ZhaoJing Li
Nov 26, 2020·Aging·Jia WangChanggang Sun
Aug 10, 2021·Journal of Oncology·Ya LiLiang Zhou